ReviewCurrent opinion in chemical biology2013
The human microbiome is a source of therapeutic drug targets.
Review in Current opinion in chemical biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Human gut microbiota-derived antimicrobials against Salmonella Typhi: diversity, mechanisms, and therapeutic potential.Archives of microbiology · 2025Review
- Design, synthesis, and biological evaluation of (thio)urea derivatives as potentJournal of enzyme inhibition and medicinal chemistry · 2024Article
- The Impact of Microbiota-Immunity-Hormone Interactions on Autoimmune Diseases and Infection.Biomedicines · 2024Review
- Positive interactions are common among culturable bacteria.Science advances · 2021Article
- Succinylsulfathiazole modulates the mTOR signaling pathway in the liver of c57BL/6 mice via a folate independent mechanism.Experimental gerontology · 2021Article
- Multi-Omics Approaches: The Key to Improving Respiratory Health in People With Cystic Fibrosis?Frontiers in pharmacology · 2020Review
- Precision Medicine Goes Microscopic: Engineering the Microbiome to Improve Drug Outcomes.Cell host & microbe · 2019Review
- Active site flexibility revealed in crystal structures of Parabacteroides merdae β-glucuronidase from the human gut microbiome.Protein science : a publication of the Protein Society · 2018Article
- Three structurally and functionally distinct β-glucuronidases from the human gut microbeThe Journal of biological chemistry · 2018Article
- Gut microbes as future therapeutics in treating inflammatory and infectious diseases: Lessons from recent findings.The Journal of nutritional biochemistry · 2018Review
- Gut-Brain Psychology: Rethinking Psychology From the Microbiota-Gut-Brain Axis.Frontiers in integrative neuroscience · 2018Review
- Chemical reaction vector embeddings: towards predicting drug metabolism in the human gut microbiome.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2018Article
- Microbiome at the Frontier of Personalized Medicine.Mayo Clinic proceedings · 2017Review
- Symbiosis-inspired approaches to antibiotic discovery.Natural product reports · 2017Review
- Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin.Archives of toxicology · 2017Article
- The intestinal microbiome and surgical disease.Current problems in surgery · 2016Review
- Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.Chemistry & biology · 2015Article
- Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches.Frontiers in microbiology · 2015Review
- The microbiota, chemical symbiosis, and human disease.Journal of molecular biology · 2014Review
- Irritable bowel syndrome: a microbiome-gut-brain axis disorder?World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
It was appreciated early in drug discovery that the microbiota play an important role in the efficacy of therapeutic compounds. Indeed, the first antibiotic sulfa drugs were shown in the 1940s to be transformed by the bacteria that encode what we now call the intestinal microbiome. Here we briefly review the roles symbiotic bacteria play in the chemistry of human health, and we focus on the emerging appreciation that specific enzyme targets expressed by microbial symbiotes can be selectively disrupted to achieve clinical outcomes. We conclude that components of the microbiome should be considered 'druggable targets,' and we suggest that our rapidly evolving understanding of the chemical biology of mammalian-microbial symbiosis will translate into improved human health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.